Data Reporting Problems
|
|
|
- Tyler Allison
- 10 years ago
- Views:
Transcription
1 Data Reporting Problems Shelley Hewerdine & Khrystyna Valkiv Istanbul, 23rd March 2015 #EBMT2015
2 Format of this session Recent EBMT Registry work Improving Data Quality Data reporting Quiz Your questions 2
3 How the data is used The Registry provides a pool of data to perform retrospective studies, assess epidemiological trends, or prepare prospective trials. Collected data on >500,000 transplants since they began in the 1970s. For basic and clinical Research Standardisation and Quality Control Accreditation (JACIE) Requirements - Health Authorities and Commissioners EBMT Membership requirements: MED-A for every transplant performed 3
4 Importance of good data Data as accurate and complete as possible for research and quality management Missing data and missing follow ups can skew data or lead to a statistical bias Follow up: very important part of the Registry, research helping to improve quality of life, long term. Example of centre reporting follow up only when something happens (Centre A) and a centre systematically reporting follow ups (Centre B): 4
5 Overall survival for Centres A and B Centre B 0.25 Centre A Years 5
6 1.00 Length of follow up Centres with same outcome may look worse when follow up is shorter =< 5 years >10 years >5 and =<10 years Years 6
7 Working to improve the data Tidy Up Your Data campaign. Have run a full list of data quality queries and sent to centres. (ProMISe users encouraged to run them to check data) 7
8 Tidy Up Your Data: list of report queries Diagnosis labelled as other or unknown (Main Classification only) Diagnosis sub classification labelled as other or unknown Best Response_Status after HSCT is Null and_or Unknown Disease status at HSCT is Null and_or Unknown Missing number of Disease status at HSCT No relapse prior to 2nd or subsequent HSCT Cause of death is GvHD but no GvHD recorded Cause of death is relapse but no relapse recorded Last assessment is HSCT assessment Patient alive with a cause of death Hospital or Unit unique patient number (UPN) missing Hospital unique patient number (UPN) shared by two patient records Patient date of birth missing Possible duplicate entry of same patient Allogeneic HSCT without a donor Source of stem cells missing 8
9 Working to improve the data: further requests ed all centres with a list of patients that have not had a follow up reported for 5 years or more. Aim to send these more regularly: twice a year Missing MED-A: requests sent to centres sending in data forms. Aim to widen requests to target more ProMISe users Duplicate registrations: many s have been sent to query possible duplicates in centres and clean up the doubles Thank you for helping with our data quality requests 9
10 Quiz Quiz handouts 8 questions. Have a look in pairs or groups of 3 for approx minutes 10
11 Quiz: Solutions 1. Which of the following should NOT be reported as a transplant registration? Answer b) Autologous reinfusion after graft failure This is not considered as a transplant. Check transplant definitions at the beginning of the MED-AB manual. Ask clinician or registry helpdesk if unsure. A boost is an infusion of cells from the same donor without conditioning, with the same donor being present in a proportion higher than 10% If cells are not from same donor OR there is conditioning OR donor cells are present at a lower proportion than 10%, then it is a genuine transplant. Please also report patients who die between conditioning and transplant. We enter the day 0 info and put the planned HSCT date as the date of death 11
12 Quiz: Solutions 2. A patient received Rituximab as a treatment for EBV or CMV reactivation, but you can t find this in the MED-A form, what should you do? This treatment is not part of the EBMT data collection. Can be entered in the database by advanced users, but unlikely to be analysed. Centres can record data for own use if preferred Recommendation: keep to MED-AB. And if you report MED-A but find you want to record MED-B items, report MED-B! 12
13 Quiz: Solutions 3. A patient has a rare diagnosis and you cannot find the right disease classification sheet or code. What do you do? Answer: b) Check the disease classifications list on the EBMT website If cannot find or unsure, answer c) Contact the registry helpdesk Answer a) Enter it in the database as uncoded is a no-no. It is very rare for diseases to be uncoded. Only enter an uncoded diagnosis if we advise you to. 13
14 Quiz: Solutions 4. In 2005 the percentage of transplant registrations with the best response at 100 days missing or unknown was 12%. Do you think this percentage has increased or decreased for recent registrations (2013 transplants)? Answer: decreased. The number of registrations with this item missing/unknown in 2013 was 7% Improvement over time: number of missing MED-A items decreased: 14
15 EBMT Registry Missing data items - average per HSCT Med-A submission Number of centres < 5 missing items 5-10 missing items >10 missing items % 80% 70% Percentage of centres 60% 50% 40% 30% 20% 10% 0% < 5 missing items 5-10 missing items >10 missing items 15
16 Quiz: Solutions Remember you can run a report on the best response missing item, plus display records without disease status at transplant (and number of the status) properly filled. Crucial data quality reports on identifiers: Unique UPN per patient per centre Possible duplicates: all transplants need to go in one single patient record, no matter where performed or the number of transplants (Request form to access original transplant in other centre) Ensure date of birth and patient gender are filled 16
17 Quiz: Solutions 5. If a patient has more than one transplant, when should follow up be reported? Answer: b) Between transplants, then annually after the most recent transplant We will try to improve our data forms to help capture the follow up between transplants. Again a DQ report: No relapse prior to 2nd or subsequent HSCT 17
18 Quiz: Solutions 6. Donor Lymphocyte Infusions (DLI): Must all the infusions of the same regimen (given for the same indication within 10 weeks) be recorded separately, or must only the 1st infusion of the regimen be recorded with the total number of infusion in this regimen (without entering details for each infusion)? Answer: only the 1 st infusion of each 10 week cycle needs to be reported, giving the total number of infusions 18
19 Quiz: Solutions 7. What is the best way to send electronic data files to EBMT? E.g. scanned forms, HLA reports, Excel files with study or data queries Correct answer: b) send by with password protection or c) use secure download facility in Promise. c) ideally best, available Promise 3. Answer a) Just send by is a no-no for files containing identifiers, but continues to happen. 19
20 Quiz: Solutions 8. MED-A follow up form: discrepancies Cause of death is relapse, but relapse data not recorded. (Also may happen with gvhd). DQ reports available for both No date of last contact (also may happen with Excel requests) 20
21 Conclusions Positive response to Tidy Up Your Data and 5 Year follow up Decrease in number of missing items in MED-A Cleaning the duplicate registrations and shared UPNs. <400 possible doubles. Shared UPNs halved. Thank you for all your help and cooperation with the data, and the quality! 21
22 Your Questions? 22
23 Related Sessions EBMT 2015 Please complete feedback form.. then join us for a drink! Data Managers Reception Room 3B10 Tuesday 09:00 09:40 Changes to MED-A Please complete feedback forms 10:00 12:00 (computer room) HLA Data Entry :00 Introduction to HSCT and the MED-A form 14:00 15:30 (computer room) Avoiding & solving problems in ProMISe 14:45 15:25 Data Managers & Literature 23
OUR JOURNEY THROUGH THE YEARS
The King Faisal Specialist Hospital and Research Centre Experience in Hematology, Oncology and Bone Marrow Transplantation OUR JOURNEY THROUGH THE YEARS REGGIE BELKHEDIM A Brief Overview: King Faisal Specialist
The future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings. Prof. Tony Pagliuca
The future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings Prof. Tony Pagliuca UK STEM CELL STRATEGIC FORUM The future of unrelated donor SCT in the UK Antonio Pagliuca, Transplant
storage and handling of unused stem cell products Swiss consensus?
storage and handling of unused stem cell products Swiss consensus? 16. Jan. 2015 Panagiotis Samaras, Mario Bargetzi stored units USZ Type of unused product autologous stem cells never transplanted 2nd
Portal Technical Requirements
Portal Technical Requirements The CLINT project is going to build an infrastructure to support the conduct of international prospective clinical trials in autologous and allogeneic stem cell transplantation.
Umbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation V Rocha MD, PhD Hopital Saint Louis, Paris University 7 CIBMTR Milwaukee Umbilical Cord blood transplantation Background History Clinical results in children and adults
Reference: NHS England B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
Corporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
Bone Marrow/Stem Cell Transplant
Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based
Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE
UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION
The CIBMTR Audit Program
The CIBMTR Audit Program Amy Hays and Krista Sullivan November 7, 2008 Objectives Audit rationale and goals Overview of audit program Audit process Audit follow-up Why are audits performed? Audit Rationale
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is
Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
STEM CELL THERAPEUTIC OUTCOMES DATABASE
C W Bill Young Cell Transplantation Program STEM CELL THERAPEUTIC OUTCOMES DATABASE BUS06_1ppt Stem Cell Therapeutic and Research Act of 2005 (PL 109-129) 129) Authorizing law, preceded by efforts to:
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP)
Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP) October 18, 2014 19th Congress of APBMT, Hangzhou, China AMIR ALI HAMIDIEH, MD Iranian
Improving Quality in Cellular Therapy with FACT Accreditation. The Foundation for the Accreditation of Cellular Therapy
Improving Quality in Cellular Therapy with FACT Accreditation The Foundation for the Accreditation of Cellular Therapy 1 Goals and Services of FACT Promote quality patient care and laboratory practice
A Cure for Sickle Cell Anemia and Thalassemia
IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology
Background: 1) Does your center have effective ways of collecting data from multiple sources to submit to multiple organizations?
University of Michigan Best Practices Pam James, MS CCRP Administrative Manager, Data Management Bone Marrow Transplant, Hematologic Malignancies & NCCN Background: The data management team at the University
Corporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
EUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases
! 21%! EUROCORD 6756 cord blood transplantations performed from 1988 to March 2010 in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases * missing center
2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders
UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,
The donor search: the best donor or cord blood unit
The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation
Outline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa
Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem
Infosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?
Infosheet Allogeneic stem cell transplantation in myeloma High-dose therapy and autologous stem cell transplantation is currently the first-line treatment standard of care for younger/fitter myeloma patients.
How to select a donor and product for allogeneic HCT
How to select a donor and product for allogeneic HCT Dr Bronwen Shaw 10 February 2015 Overview Who (and where) are the donors What factors determine how we choose between them Acquisition Clinical Donor
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
Integrating Quality Reporting into the Electronic Medical Record
Integrating Quality Reporting into the Electronic Medical Record February 28, 2014 Karen Collum, MSN, RN, OCN Clinical Program Nurse Leader Transplant Service www. MSKCC.org OVERVIEW Objectives Introduction
On April 4, a group of physicians at the 37th annual
By Ronale Tucker Rhodes, MS Better gene sampling and newer transplant regimens are making stem cell transplantation possible for a host of disease states that previously were rarely considered for this
Challenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute
Challenges of Hematopoietic Stem Cell Transplantation Robert J. Soiffer, MD Dana Farber Cancer Institute Hematopoietic Stem Cell Transplantation Objectives Deliver sufficient chemo-radio therapy to destroy
Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
Cord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program
Cord Blood: that other stem cell source Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program CBMTG April 2012 The problem: In order to perform a BMT from one person to another one needs
Aggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
Selection of the Optimal Umbilical Cord Blood Unit
Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies
Blood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012
Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit Karen Ballen, MD Massachusetts General Hospital June, 2012 OUTLINE Cell Dose HLA Typing HLA C and KIR HLA Antibodies ABO and Racial/Ethnic
The Danish Bone Marrow Donor Registry DBMDR
The DBMDR Vision To achieve and maintain a position as an internationally recognized hematopoietic stem cell donor registry with respect to high quality of donor data base and HLA typing, individualized,
Corporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
Stammzelltransplantation. Neues vom immunologischen Ctrl-Alt-Del
Allogene Neues vom immunologischen Ctrl-Alt-Del Prof. Dr. med. Wolfgang Bethge Allogene am ASH Insgesamt 715 Abstracts zum Thema Auswahl: Azacitidine als Überbrückung zu allogenen SZT bei MDS Ergebnis
Treatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
Epstein-Barr virus-associated lymphoproliferative disease following allogeneic stem cell transplantation
Epstein-Barr virus-associated lymphoproliferative disease following allogeneic stem cell transplantation Dr Christopher Fox Consultant Haematologist Nottingham University Hospitals NHS Trust The Herpesvirus
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
WBMT Global Survey. Helen Baldomero Cape Town November 2014. Worldwide Network for Blood and Marrow Transplantation
WBMT Global Survey Helen Baldomero Cape Town November 214 NGO in official relations with World Health Organization Leukemias LPD Solid tumors Non - Malignant disorders NGO in official relations with World
PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA
2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate
ILNA CODING GUIDELINES
ILNA CODING GUIDELINES ONS/APHON Chapters and ONCC Renewal Candidates There are more than 37,000 oncology certified nurses many of them are actively looking for CE they can use for certification renewal
EBMT European Society for Blood and Marrow Transplantation MED-AB FORMS MANUAL
EBMT European Society for Blood and Marrow Transplantation MED-AB FORMS MANUAL A Guide to the completion of the EBMT HSCT Med-AB Forms Copyright by EBMT, 2010 All rights reserved INTRODUCTION The present
Not for publication or presentation
MINUTES CIBMTR WORKING COMMITTEE FOR GVHD Orlando, Florida Thursday, February 25, 2010, 2:45 pm 4:45 pm Statisticians: Scientific Directors: Steven Pavletic MD, National Cancer Institute Telephone: 301-402-4899;
cancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146
Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer
Graft Failure After HSCT
Graft Failure After HSCT Vanderson Rocha, MD, PhD Professor of Haematology- Oxford University Bone Marrow Transplant Unit- Sirio Libanes Hospital- Sao Paulo Scientific Director of Eurocord-Paris Clinical
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. April 2013. Reference: NHSCB/B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation First published:
Directed/Related Cord Blood Collection by NHS Blood and Transplant
Directed/Related Cord Blood Collection by Jacqui Thompson Clinical Scientist Section Head of Specialist Procedures Stem Cells and Immunotherapies Department National Blood Service, NHSBT Birmingham Why
Selecting an appropriately matched donor for hematopoietic
Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation
Lymphomas after organ transplantation
Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative
A fact sheet UNRELATED BONE MARROW AND CORD BLOOD STEM CELL TRANSPLANTS
A fact sheet UNRELATED BONE MARROW AND CORD BLOOD STEM CELL TRANSPLANTS Each year, thousands of patients are diagnosed with diseases treatable by a blood stem cell transplant. These blood stem cells can
UMBILICAL CORD BANKING. (formerly Unistem Biosciences Pvt.Ltd.)
UMBILICAL CORD BANKING (formerly Unistem Biosciences Pvt.Ltd.) INITIATIVES OF CELLUGEN BIOTECH PVT.LTD. (formerly Unistem Biosciences Pvt.Ltd.) UMBILICAL CORD BANKING UMBILICAL CORD STEM CELL THERAPY Stem
Singapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013. National Registry of Diseases Office (NRDO)
Singapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013 National Registry of Diseases Office (NRDO) Released November 3, 2014 Acknowledgement This report was
Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis
Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,
New Zealand Bone Marrow Donor Registry
Title: Authorised by: SECTION 9.0 NZBMDR STANDARDS PROCESS FOR AN UNRELATED STEM CELL DONOR WORKUP & IDENTIFICATION OF CORD BLOOD UNITS Executive Officer Contributing Authors: Sally Gordon Dr Hilary Blacklock
Chapter 2 History of MD Anderson s Tumor Registry
Chapter 2 History of MD Anderson s Tumor Registry Sarah H. Taylor The Tumor Registry Department at The University of Texas MD Anderson Cancer Center is responsible for a database that contains demographic
Epstein-Barr Virus (EBV) complications following HSCT: from viremia to post transplant lymphoproliferative disease (PTLD) and lymphoma
Epstein-arr Virus (EV) complications following HSCT: from viremia to post transplant lymphoproliferative p disease (PTLD) and lymphoma Laurie A. Milner, MD Associate Professor, Pediatric Hematology / Oncology
CSHCN Services Program Prior Authorization Request for Stem Cell or Renal Transplant Form and Instructions
CSHCN Services Program Prior Authorization Request for Stem Cell or Renal Transplant Form and Instructions General Information Ensure the most recent version of the Prior Authorization Request for Stem
Summary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status
of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Shelley Grant Branch Chief, Blood Stem Cell Transplantation Program September 11, 2015 Overview December 20, 2005 - HRSA began
H. R. 2107 IN THE HOUSE OF REPRESENTATIVES
I 1TH CONGRESS 1ST SESSION H. R. 2107 To direct the Secretary of Health and Human Services to conduct a public education campaign on umbilical cord blood stem cells, and for other purposes. IN THE HOUSE
Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION
CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation
Cord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014
Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
Preparing for the CIBMTR Data Audit
Preparing for the CIBMTR Data Audit Fiscal Year Prior to Audit Send notice of upcoming audit to Receive additional audit related center materials Send additional audit educational materials to audit contact
Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.
Health Disparities in Multiple Myeloma Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc. Multiple Myeloma Overview Multiple myeloma (MM) is a type of blood cancer that develops
Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA
STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA OVO CLINIC I 8000 BLVD DECARIE, MONTREAL QC H4P 2S4 I 514.798.2000 I OVOCLINIC.COM 2 a therapeutic revolution As the
Workshop on Patient Support and Market Research Programmes
Workshop on Patient Support and Market Research Programmes Spectrum of programmes falling under the terms of PSP and MRPs and the and the type of safety data collected Pharmaceutical Industry Associations
Cord blood donation is a painless and free gesture, helping others and saving lives.
Cord blood donation is a painless and free gesture, helping others and saving lives. Cord blood, a bond for life. GRANDE CAUSE NATIONALE 2009 Donation for scientific research If your donation does not
Stem Cell Transplantation for Acute Lymphoblastic Leukemia
Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic
Graft-versus-host disease (GvHD)
Graft-versus-host disease (GvHD) This information is an extract from the booklet Understanding donor stem cell (allogeneic) transplants. You may find the full booklet helpful. We can send you a free copy
What is a Stem Cell Transplantation?
What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am
Instructions for Pre-Transplant Essential Data (Pre-TED) Form (Revision 4) TABLE OF CONTENTS
Instructions for Pre-Transplant Essential Data (Pre-TED) Form (Revision 4) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Pre-Transplant Essential Data
Tips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD
Tips for surviving the analysis of survival data Philip Twumasi-Ankrah, PhD Big picture In medical research and many other areas of research, we often confront continuous, ordinal or dichotomous outcomes
Safe Blood Sampling Training Package
Better Blood Transfusion - Education Programme Safe Blood Sampling Training Package SBS Training Package version 2010 to SNBTS www.learnbloodtransfusion.org.uk Learning Outcomes Following this session
How To Save A Patient From A Cancer
BIOSTATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH Blood-&-Marrow Transplants & CANCERS Stem Cells Stem cells are immature body cells that act like "starter dough" because they can make identical copies
